Recent preclinical studies and clinical trials suggest that bone marrow–derived cell preparations, including mononuclear bone marrow cells
1-6 and mesenchymal stem cells,
7,8 ameliorate left ventricular (LV) remodeling with acute
4,7 myocardial infarction (MI) and chronic
1-3,5,8,9 ischemic cardiomyopathy. An effective antiremodeling, proregenerative treatment for ischemic cardiomyopathy would address a major unmet need for many patients. By virtue of their greater differentiation potential,
10 the culture-expanded mesenchymal stem cells constituent of bone marrow is speculated to have potential for forming ectopic tissue
11 or stimulating tumors
12 but could also have greater antifibrotic and proregenerative effects than bone marrow mononuclear cells.
13 An unresolved issue is whether mesenchymal stem cells have similar safety and possibly greater efficacy than bone marrow mononuclear cells.
8